¶ Inclisiran for Lewy Body Dementia Trial
Inclisiran (brand name: Leqvio®) is a small interfering RNA (siRNA) therapeutic originally developed for cardiovascular disease that is being investigated for potential use in Lewy body dementia (LBD). It works by silencing the PCSK9 gene to modify lipid metabolism, which may have implications for neurodegeneration through vascular mechanisms.
Clinical Trial Identifier: NCT05669703
| Field |
Value |
| Phase |
Phase 2 |
| Status |
Ongoing |
| Drug |
Inclisiran (Leqvio®) |
| Mechanism |
PCSK9 gene silencing (siRNA) |
| Dosing |
Subcutaneous injection |
| Patient Population |
Patients with Lewy body dementia |
Inclisiran is a first-in-class siRNA therapeutic that:
- Targets PCSK9 (proprotein convertase subtilisin/kexin type 9) gene
- Administered via subcutaneous injection
- Provides long-lasting LDL cholesterol reduction (effective for 6+ months)
- Approved for cardiovascular disease treatment
Small interfering RNA (siRNA) drugs work through RNA interference (RNAi):
- siRNA is delivered into cells
- Incorporated into the RNA-induced silencing complex (RISC)
- Directs RISC to target messenger RNA (mRNA)
- The target mRNA is cleaved and degraded
- Gene expression is effectively "silenced"
This is different from traditional small molecule drugs - siRNA can target previously "undruggable" genes.
¶ PCSK9 and Neurodegeneration
While primarily studied for cardiovascular applications, PCSK9 may play a role in neurodegeneration:
Lewy body dementia often involves:
- Cerebrovascular disease comorbidity
- Blood-brain barrier dysfunction
- Cerebral hypoperfusion
- White matter lesions
By improving vascular health through LDL reduction, inclisiran may:
- Improve cerebral blood flow
- Reduce vascular inflammation
- Protect neuronal function
- Slow disease progression
- Primary: Safety and tolerability of inclisiran in LBD patients
- Secondary: Biomarker effects (PCSK9, LDL, inflammatory markers)
- Exploratory: Cognitive outcomes, neuroimaging changes
- Diagnosis of dementia with Lewy bodies (DLB) or Parkinson's disease dementia (PDD)
- Stable background therapy
- Adequate liver and kidney function
- Inclisiran subcutaneous injections
- Dosing schedule per protocol
- Monitoring for adverse effects
¶ PCSK9 Biology and Cardiovascular Role
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is a serine protease that plays a crucial role in LDL cholesterol metabolism:
Normal Function:
- Secreted by hepatocytes
- Binds to LDL receptor (LDLR) on hepatocyte surface
- Promotes LDLR degradation in lysosomes
- Reduces LDLR recycling to cell surface
- Result: Increased plasma LDL cholesterol
Genetic Variants:
- Gain-of-function mutations → familial hypercholesterolemia
- Loss-of-function mutations → lower LDL and reduced cardiovascular risk
- This validated PCSK9 as a therapeutic target
Monoclonal Antibodies:
- Alirocumab (Praluent®)
- Evolocumab (Repatha®)
- Bind PCSK9 in circulation
- Require frequent dosing (bi-weekly)
siRNA - Inclisiran:
- Direct hepatic delivery via GalNAc conjugation
- Silences PCSK9 gene expression
- Long-lasting effect (6+ months)
- Lower dosing frequency
The pivotal trial establishing inclisiran's efficacy:
Study Design:
- Randomized, double-blind, placebo-controlled
- 16,000+ patients with atherosclerotic cardiovascular disease
- Primary endpoint: MACE (Major Adverse Cardiovascular Events)
Results:
- Significant LDL reduction (~50%)
- Reduced cardiovascular events
- Acceptable safety profile
¶ PCSK9 and Neurodegeneration
While primarily studied for cardiovascular applications, PCSK9 may play a role in neurodegeneration:
Emerging research reveals PCSK9 has functions beyond hepatic cholesterol regulation:
Brain Expression:
- PCSK9 is expressed in neurons and glia
- Higher expression in AD and PD brain tissue
- Colocalizes with amyloid plaques and Lewy bodies
Potential Mechanisms:
- Modulation of amyloid precursor protein (APP) processing
- Effects on tau phosphorylation
- Neuroinflammatory signaling
- Synaptic function regulation
Lewy body dementia often involves:
- Cerebrovascular disease comorbidity (50-70% of patients)
- Blood-brain barrier dysfunction
- Cerebral hypoperfusion
- White matter lesions
- Small vessel disease
By improving vascular health through LDL reduction, inclisiran may:
- Improve cerebral blood flow
- Reduce vascular inflammation
- Protect neuronal function
- Slow disease progression
CSVD is a key contributor to cognitive decline in LBD:
Pathological Features:
- Lipohyalinosis of small vessels
- Fibrinoid necrosis
- Microaneurysms
- White matter hyperintensities on MRI
Relationship to LBD:
- Contributes to executive dysfunction
- Increases gait impairment
- Adds to parkinsonism
- Accelerates dementia progression
Vascular Contributions:
- Hypoperfusion → energy failure
- BBB breakdown → protein extravasation
- Microinfarcts → focal deficits
- Primary: Safety and tolerability of inclisiran in LBD patients
- Secondary: Biomarker effects (PCSK9, LDL, inflammatory markers)
- Exploratory: Cognitive outcomes, neuroimaging changes
- Diagnosis of dementia with Lewy bodies (DLB) or Parkinson's disease dementia (PDD)
- Stable background therapy
- Adequate liver and kidney function
Primary Endpoints:
- Adverse events and serious adverse events
- Discontinuation rate
- Laboratory abnormalities
Secondary Endpoints:
- Change in plasma PCSK9 levels
- Change in LDL cholesterol
- Change in inflammatory markers (IL-6, CRP)
Exploratory Endpoints:
- Cognitive assessment (MDS-UPDRS part I, MoCA)
- MRI brain volumetry
- Cerebral blood flow measurements
- CSF biomarkers (α-synuclein, tau, Aβ)
Phase 1 (Completed):
- Pharmacokinetic assessment
- Dose selection
Phase 2 (Current):
- Safety and tolerability in LBD population
- Biomarker validation
- Signal detection for cognitive outcomes
Phase 3 (Planned, if Phase 2 positive):
- Large-scale efficacy trial
- Cognitive and functional endpoints
This trial represents a novel approach to LBD treatment:
- Vascular Target: Addresses cerebrovascular components of LBD
- Repurposing: Applies proven siRNA technology to new indication
- Long-lasting Effects: Less frequent dosing than traditional therapies
- Safety Profile: Well-characterized safety from cardiovascular trials
Efficiency:
- Single dose provides months of effect
- Improved adherence
- Steady pharmacological effect
Specificity:
- Gene-specific targeting
- Minimal off-target effects
- Precise mechanism
Innovation:
- Novel therapeutic class for neurodegeneration
- Potential for combination approaches
- Addresses "undruggable" targets
¶ Comparison: LBD Treatment Landscape
| Drug/Approach |
Mechanism |
Status |
| Inclisiran |
PCSK9 siRNA |
Phase 2 |
| Donepezil/Rivastigmine |
Cholinesterase inhibition |
Approved |
| Memantine |
NMDA antagonism |
Approved |
| Levodopa |
Dopamine replacement |
Approved (for PD) |
| Duvyuatide |
Alpha-synuclein aggregation inhibitor |
Phase 2 |
| Blenrep |
Anti-amyloid antibody |
Phase 3 |
¶ Challenges and Considerations
- Blood-brain barrier: siRNA may have limited CNS penetration
- Target relevance: PCSK9's role in LBD is not fully established
- Biomarker validation: Surrogate endpoints need validation
- Vascular vs. Direct: Unclear if benefit is vascular only
The brain has distinct cholesterol metabolism:
CNS Cholesterol:
- Separate from peripheral pool
- Synthesized locally by astrocytes and neurons
- Essential for myelin, synaptic function
- Cannot cross BBB from circulation
Dysregulation Effects:
- Altered membrane fluidity
- Impaired synaptic transmission
- Myelin abnormalities
- Increased oxidative stress
¶ LDL and Alzheimer's Disease
Vascular contributions to AD are well-established:
Epidemiological:
- Mid-life hypercholesterolemia → AD risk
- Statins may reduce AD risk
- Lipid-lowering therapy associated with reduced incidence
Mechanistic:
- Amyloid processing linked to cholesterol
- Cholesterol-rich membrane domains (rafts)
- Vascular amyloid deposition (CAA)
¶ LDL and Parkinson's Disease
Similar vascular links in PD:
- Lower LDL associated with faster progression
- Statin use associated with reduced PD risk
- Vascular parkinsonism overlap
LBD shares features with both AD and PD:
- Amyloid and α-synuclein pathology
- Significant vascular comorbidity
- Cholinergic deficits
Lipid-lowering may provide:
- Reduced cerebrovascular burden
- Direct neuroprotective effects
- Improved cerebral perfusion
RNA Interference (RNAi):
- Double-stranded siRNA enters cell
- Incorporated into RISC (RNA-induced silencing complex)
- siRNA guides RISC to complementary mRNA
- Argonaute cleaves target mRNA
- Gene expression silenced
Targeted Hepatic Delivery:
- N-acetylgalactosamine (GalNAc) conjugates
- Binds to asialoglycoprotein receptor on hepatocytes
- Enables efficient liver accumulation
- Reduces off-target effects
Advantages:
- Liver-targeted delivery
- Reduced systemic exposure
- Lower doses required
- Improved safety margin
| Feature |
siRNA (Inclisiran) |
Monoclonal Antibody |
Small Molecule |
| Target |
mRNA |
Protein |
Protein |
| Duration |
6+ months |
2 weeks |
Daily |
| Delivery |
Subcutaneous |
Subcutaneous |
Oral |
| Specificity |
High |
High |
Moderate |
| CNS Penetration |
Limited |
Limited |
Variable |
Needed Biomarkers:
- Peripheral PCSK9 as CNS proxy
- Neurofilament light chain (NfL)
- α-synuclein seeding assays
- Neuroimaging markers
Potential Combinations:
- Inclisiran + cholinesterase inhibitors
- Inclisiran + α-synuclein-targeted therapy
- Inclisiran + disease-modifying antibodies
Patient Selection:
- Vascular phenotype emphasis
- Lipid profile optimization
- Genetic stratification (APOE, PCSK9 variants)
Study Design Features:
- Randomized, double-blind, placebo-controlled
- Parallel-group design with 1:1 allocation
- 52-week treatment period
- 24-week follow-up for safety
Sample Size Considerations:
- Approximately 80-100 participants
- 90% power to detect 30% reduction in LDL
- Stratified by baseline cholesterol and age
Safety Monitoring:
- Adverse event collection throughout study
- Periodic liver function testing
- Lipid panel monitoring
- Neurological assessment
Cost Considerations:
- Inclisiran costs approximately $6,500/year
- Cardiovascular trials show cost-effectiveness
- LBD burden similar to AD (~$100K/year)
- Potential to reduce institutionalization
Value Propositions:
- Long-lasting effect reduces administration burden
- Potential to delay dementia progression
- Cardiovascular benefits in mixed pathology
- Reduced caregiver burden
¶ ORION-9, ORION-10, and ORION-11 Trials
ORION-9 (Heterozygous Familial Hypercholesterolemia):
- 482 patients with HeFH
- 48% LDL reduction at 17 months
- Well-tolerated with no discontinuations
ORION-10 and ORION-11 (ASCVD):
- Over 3,000 patients with atherosclerotic cardiovascular disease
- LDL reduction of ~50%
- Sustained effect over 18+ months
ORION-4 (Outcomes Trial):
- 16,000+ patients
- Ongoing to assess cardiovascular events
- Expected completion 2024-2025
Observational Studies:
- Integrated delivery systems showing adherence benefit
- Specialty pharmacy data demonstrating persistence
- Cardiovascular registry follow-up
Post-Marketing Surveillance:
- Large-scale safety monitoring
- Rare adverse event detection
- Effectiveness in diverse populations
Arteriolosclerosis:
- Hyaline deposition in vessel walls
- Smooth muscle cell loss
- Reduced autoregulation
Lipohyalinosis:
- Fibrinoid necrosis
- Lipid accumulation
- Microaneurysm formation
Amyloid Angiopathy:
- Aβ deposition in vessel walls
- Smooth muscle degeneration
- Increased hemorrhage risk
Mechanisms:
- Tight junction disruption
- Pericyte dysfunction
- Astrocyte end-foot damage
In LBD:
- More pronounced than in AD
- Correlates with white matter lesions
- Associated with cognitive decline
Components:
Dysfunction in LBD:
- Impaired coupling
- Reduced clearance
- Increased inflammation
Alnylam Programs:
- ATTR amyloidosis (approved)
- Hepatic porphyrias (approved)
- CNS-targeted programs in development
Other Companies:
- Ionis ASOs
- Dicerna RNAi
- Arrowhead RNAi
Barriers:
- Blood-brain barrier
- Peripheral vs CNS delivery
- Target engagement verification
Approaches:
- Focused ultrasound
- AAV vectors
- Exosome delivery
Gene-Specific Silencing:
- Huntington's disease (HTT)
- SOD1 ALS
- C9orf72 ALS
Multi-Target Approaches:
- Simultaneous silencing of multiple genes
- Combination with other modalities
¶ Current Status and Future Directions
Phase 2 Progress:
- Enrollment ongoing
- Safety monitoring active
- Preliminary biomarker data expected 2026
Anticipated Timeline:
- Phase 2 completion: 2027
- Phase 3 decision: 2028
- Potential approval: 2030+
If Successful:
- Paradigm shift for LBD treatment
- Vascular pathway validation
- siRNA application in dementia
If Negative:
- Refines understanding of LBD biology
- Informs future vascular targeting
- Guides patient selection
Daily Management:
- LBD requires 24/7 supervision in advanced stages
- Fluctuating cognition creates unpredictable needs
- Behavioral symptoms challenging to manage
Treatment Burden:
- Multiple daily medications common
- Frequent medical appointments
- Therapy and rehabilitation sessions
Inclisiran Potential Benefits:
- Semi-annual dosing simplifies regimen
- Cardiovascular protection
- Potential to slow progression reduces care burden
Domains Affected:
- Physical function (gait, fall risk)
- Cognition (memory, executive function)
- Behavior (hallucinations, depression)
- Autonomic (orthostasis, constipation)
Treatment Goals:
- Maintain independence
- Reduce hospitalizations
- Support community living
- Improve caregiver wellbeing
¶ Competitive Landscape
Statins:
- Widely used, well-characterized
- Mixed evidence in dementia
- Generic, low cost
- No large-scale LBD trials
PCSK9 Antibodies:
- Alirocumab, Evolocumab
- Frequent dosing (bi-weekly)
- Approved for cardiovascular disease
- Not studied in LBD
Bempedoic Acid:
- ATP citrate lyase inhibitor
- Oral, once-daily
- Lower LDL modestly
- Limited CNS data
| Approach |
Dosing |
LDL Reduction |
LBD Data |
Cost |
| Inclisiran |
6 months |
~50% |
Ongoing |
$$$ |
| Statins |
Daily |
20-55% |
Mixed |
$ |
| PCSK9 mAbs |
2 weeks |
~60% |
None |
$$$$ |
| Bempedoic Acid |
Daily |
~17% |
None |
$$ |
The inclisiran LBD trial represents an innovative approach to treating dementia by targeting vascular contributions to neurodegeneration. By repurposing a proven cardiovascular therapy with a novel mechanism, this trial addresses the significant vascular component often present in LBD pathophysiology.
Key aspects of this trial:
- First siRNA therapeutic evaluated in LBD
- Targets PCSK9 for lipid-lowering
- Leverages vascular hypothesis
- Builds on cardiovascular safety data
The trial's success would establish a new therapeutic paradigm in dementia care, recognizing the importance of vascular health in neurodegenerative diseases. Even negative results will advance our understanding of LBD biology and guide future development of vascular-targeted approaches.